Ocean Biomedical announces findings in EGFR-mutant lung cancer
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...
Scientists peel away the mystery of JAK enzymes, which play roles in everything from eczema to ulcerative colitis
Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...
Cure Today1d
FDA Approval of Calquence Combo Brings Optimism in MCL
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
The American Journal of Managed Care5d
Discontinuing Versus Switching BTK Inhibitors for Toxicity
Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...
Too Old to Operate9d
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.
Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
Cure Today5d
Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...
Nature10d
The anaplastic lymphoma kinase in the pathogenesis of cancer
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified in a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCL), a subset of T-cell non ...
BioWorld6d
TYK2s to tango, TED dead? Alumis/Acelyrin merger a capital idea
In a deal that Cantor Fitzgerald analyst Eric Schmidt characterized as “capital recycling at its best,” Alumis Inc. and Acelyrin Inc. are merging in an all-stock transaction. The combined pipelines ...
The American Journal of Managed Care12d
Switching Between BTK Inhibitors in CLL
Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...
ophthalmologytimes16d
Tyrosine kinase inhibitor: An alternative treatment for non–small-cell lung cancer metastasis to the choroid
Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment ...